Contact us Demo our platform

Metabolon @

ARVO 2025

Metabolon at ARVO 2025 Annual Meeting 

Dates: May 4–8, 2025 
Location: Salt Lake City, Utah 
Visit the Official Event Website 

Join Metabolon at ARVO 2025 

Metabolon is attending the 2025 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), the premier global event dedicated to vision and ophthalmology research. This meeting brings together leading scientists, clinicians, and industry professionals to discuss the latest advancements in eye health, disease mechanisms, and therapeutic developments. 

About ARVO 2025 

The ARVO Annual Meeting is the largest and most influential conference in vision research, attracting experts from academia, industry, and clinical practice. The event provides a platform for cutting-edge scientific presentations, interactive discussions, and collaborations aimed at advancing treatments for retinal diseases, glaucoma, ocular oncology, corneal disorders, and more. 

With a diverse program covering fundamental research to clinical applications, ARVO fosters the exchange of knowledge that accelerates innovation in vision science. 

Scientific Themes and Program Highlights 

ARVO 2025 will feature high-impact research, technological advancements, and emerging therapies in vision and ophthalmology, with key themes including: 

  • Retinal Disease and Therapeutics – Advances in age-related macular degeneration (AMD), diabetic retinopathy, and gene therapy. 
  • Corneal and Ocular Surface Disorders – Innovations in transplantation, tissue engineering, and wound healing. 
  • Glaucoma and Optic Neuropathy – New insights into pathophysiology, biomarkers, and neuroprotection strategies. 
  • Ocular Oncology and Genetics – Precision medicine approaches and genetic underpinnings of eye diseases. 
  • Metabolomics in Ophthalmology – The role of metabolism and biomarkers in eye health and disease. 

View the Schedule at a Glance 

Why Metabolon is Attending ARVO 2025 

Metabolomics is playing a critical role in vision science by uncovering metabolic pathways linked to ocular diseases, therapeutic responses, and biomarker discovery. As a global leader in metabolomics, Metabolon provides comprehensive solutions to support multiomics research into genetic, environmental, and lifestyle factors effecting ophthalmology. 

At ARVO 2025, Metabolon will highlight how our metabolomics and bioinformatics capabilities are advancing ophthalmology research by: 

  • Revealing metabolic signatures of eye diseases, helping identify novel biomarkers for early diagnosis and treatment monitoring. 
  • Enhancing drug development workflows for retinal and corneal disorders, providing metabolic insights that improve therapeutic efficacy and precision medicine approaches. 
  • Supporting ophthalmic disease research by integrating metabolomics with genomics and proteomics to deliver a holistic understanding of disease mechanisms. 
  • Advancing neuro-ophthalmology studies by characterizing metabolic changes in glaucoma, optic neuropathy, and neurodegenerative eye diseases. 
  • Contributing to population health studies by examining the metabolic impact of diet, environmental factors, and systemic diseases on eye health. 

Metabolon is committed to transforming ophthalmic research by delivering data-driven insights that enhance precision medicine, disease prevention, and therapeutic innovation. 

ARVO 2025 will feature top vision science researchers presenting the latest discoveries in ophthalmology and vision research. Stay tuned for the official speaker lineup and session details. 

View All Speakers and Sessions 

Where to Find Metabolon at ARVO 2025 

We will provide details on our booth location and exhibition activities as the event approaches. To schedule a meeting with our metabolomics and bioinformatics specialists, please use the contact form on this page. 

Schedule a Meeting

Latest Resources

Access a wealth of valuable resources to deepen your understanding about metabolomics and the scientific advancements it has empowered.

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.